EcoDrugPlus

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSSTOG00000021231
Gene Symbol: TUBB4B
4 Cross references
316 Possible Orthologues:

Tubulin Beta 6 Class V

Ensembl ID : ENSSTOG00000021203
Gene Symbol: TUBB6
3 Cross references
141 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSSTOG00000022774
Gene Symbol: TP53
3 Cross references
253 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSTOG00000004286
Gene Symbol: TYR
4 Cross references
266 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSSTOG00000026422
Gene Symbol: TH
4 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSSTOG00000003264
Gene Symbol: TYK2
4 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSSTOG00000005750
Gene Symbol: TIE1
4 Cross references
203 Possible Orthologues:

Utrophin

Ensembl ID : ENSSTOG00000006062
Gene Symbol: UTRN
3 Cross references
251 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSSTOG00000008877
Gene Symbol: VEGFA
3 Cross references
253 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSSTOG00000026741
Gene Symbol: VDR
3 Cross references
458 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSSTOG00000000631
Gene Symbol: VKORC1
3 Cross references
189 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1h-Like

Ensembl ID : ENSSTOG00000022453
Gene Symbol: LOC101967418
2 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).